Tuesday, September 21, 2010
Big Money...the Pfizer-Government Influence
Pfizer spent $2.3 million lobbying federal government in 2Q on health, economic issues
09/20/10 5:00 AM PDT
NEW YORK — Pfizer Inc., the world's biggest drugmaker, spent $2.3 million lobbying Congress and federal agencies in the second quarter on health care reform and other health economic issues, according to a recent filing.
The maker of cholesterol blockbuster Lipitor, impotence pill Viagra and children's vaccine Prevnar reduced its spending on lobbying in the second quarter by 60 percent compared with a year ago when its lobbying cost $5.6 million. It is also down 48 percent from the $4.3 million in the first quarter of this year.
New York's Pfizer lobbied on multiple trade agreement issues, including China, South Korea, and Mexico. It also lobbied on health care reform issues, including the use of research comparing the effectiveness of medications and other types of treatment, health information technology, and veterans health issues.
During the April to June period, the company also lobbied on patent reform and prices and rebates for drugs bought through government programs such as Medicare and Medicaid.
Besides Congress, Pfizer lobbied the White House, the Food and Drug Administration, the Centers for Medicare and Medicaid Services, the U.S. Patent and Trademark Office and the departments of Commerce, State, Veterans Affairs and Health and Human Services, according to the July 20 filing with the House clerk's office.